Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355569 | 0.84 | SMN1; SMN2 (0.37) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL16751925 | 0.81 | ALDH1A1 (0.34) | ALDH1A1HPGDTSHRRAB9ANPC1 | |
| SCHEMBL2592035 | 0.78 | ALDH1A1 (0.42) | ALDH1A1HPGDSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12894510 | 0.78 | ALDH1A1 (0.45) | ALDH1A1HPGDTSHRRAB9ANPC1 | |
| SCHEMBL11833656 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HPGDTSHRGPR35SMN1; SMN2 | |
| SCHEMBL18356097 | 0.76 | GSK3B (0.43) | ALDH1A1HPGDTSHRMAPT | |
| SCHEMBL3655946 | 0.76 | ALDH1A1 (0.61) | ALDH1A1HPGDTSHRGPR35SMN1; SMN2 | |
| SCHEMBL289991 | 0.75 | ALDH1A1 (0.43) | ALDH1A1HPGDSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL34473107 | 0.74 | CASP3 (0.32) | — | |
| SCHEMBL560401 | 0.74 | GPR35 (0.40) | ALDH1A1HPGDTSHRGPR35SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720041-A2 | N-(1H-INDOL-2-YL)METHYL)-4-ETHYNYL-PICOLINAMIDE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Allorion Therapeutics Inc (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc | 2025-01-23 | — | — | US | disclosed |
| WO-2024240241-A2 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc (US) | 2024-11-28 | — | — | WO | disclosed |
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | disclosed |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-19 | — | — | US | disclosed |
| EP-3468971-B1 | NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-3468971-A1 | NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2019-04-17 | — | — | EP | disclosed |
| CN-109563094-A | Acyclic derivatives, their preparation method and the pharmaceutical composition containing them that new (miscellaneous) aryl replaces | 法国施维雅药厂 | 2019-04-02 | — | — | CN | disclosed |
| US-8765797-B2 | TG2 inhibitors and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-01 | — | — | US | disclosed |
| US-4154844-A | ANTIHISTAMINE, GASTRIC JUICE ANTISECRETORY AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
| US-4151288-A | ANTHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-04-24 | — | — | US | disclosed |
| US-4137234-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4137237-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4070475-A | THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-24 | — | — | US | disclosed |
| US-4024271-A | INHIBITORS OF HISTAMINE ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4018931-A | INHIBITION OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-3950333-A | HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
| US-3950353-A | HISTAMINE INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB3, ERBB2 | ALDH1A1 4536/4885HPGD 4268/4885TSHR 621/4885 |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, BCL2, CCNK | ALDH1A1 1524/4885HPGD 473/4885TSHR 3542/4885 |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CCNK | ALDH1A1 1524/4885HPGD 473/4885TSHR 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.